Antipsychotic Dosing and Concurrent Psychotropic Treatments for Medicaid-Insured Individuals With Schizophrenia

摘要: Antipsychotic medications have been first line treatment for schizophrenia half a century, yet few studies assessed outpatient maintenance in large populations. This article describes oral antipsychotic dosing patterns and psychotropic treatments using computerized Medicaid claims data individuals who were diagnosed with received on an basis during 1991. The findings show that the mean daily dose was 729 +/- 586 chlorpromazine equivalents (CPZ-EQ) high-potency agents 304 328 CPZ-EQ low-potency agents. Males, younger individuals, African-Americans larger doses of agents, ranging from 747 to 800 CPZ-EQ. Antiparkinsonian prescribed over 90 percent exposure. In summary, young adults, males, given at exceeded maximum recommended levels, despite well-established evidence high-dose offers no additional benefit. Likewise, concurrent antiparkinsonian 1990 World Health Organization recommendations.